IQVIA Holdings Inc. (NYSE:IQV) Stake Increased by AMG National Trust Bank

AMG National Trust Bank grew its holdings in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 29.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,937 shares of the medical research company’s stock after purchasing an additional 437 shares during the period. AMG National Trust Bank’s holdings in IQVIA were worth $351,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of IQV. HighTower Advisors LLC increased its stake in shares of IQVIA by 2.4% in the first quarter. HighTower Advisors LLC now owns 5,055 shares of the medical research company’s stock worth $1,168,000 after acquiring an additional 118 shares during the last quarter. Prudential PLC acquired a new position in shares of IQVIA in the first quarter worth $741,000. Baird Financial Group Inc. increased its stake in shares of IQVIA by 2.3% in the first quarter. Baird Financial Group Inc. now owns 99,566 shares of the medical research company’s stock worth $23,021,000 after acquiring an additional 2,201 shares during the last quarter. Parkside Financial Bank & Trust increased its stake in shares of IQVIA by 59.0% in the first quarter. Parkside Financial Bank & Trust now owns 388 shares of the medical research company’s stock worth $90,000 after acquiring an additional 144 shares during the last quarter. Finally, Covestor Ltd increased its stake in shares of IQVIA by 82.2% in the first quarter. Covestor Ltd now owns 554 shares of the medical research company’s stock worth $128,000 after acquiring an additional 250 shares during the last quarter. Hedge funds and other institutional investors own 86.20% of the company’s stock.

IQVIA Stock Performance

Shares of IQVIA stock opened at $225.78 on Wednesday. The company has a debt-to-equity ratio of 2.29, a current ratio of 0.90 and a quick ratio of 0.90. The firm has a market cap of $41.94 billion, a P/E ratio of 36.77, a P/E/G ratio of 2.40 and a beta of 1.37. The firm has a 50 day simple moving average of $212.77 and a 200 day simple moving average of $211.43. IQVIA Holdings Inc. has a fifty-two week low of $165.75 and a fifty-two week high of $256.62.

IQVIA (NYSE:IQV – Get Rating) last issued its quarterly earnings results on Wednesday, October 26th. The medical research company reported $2.23 earnings per share for the quarter, beating analysts’ consensus estimates of $2.19 by $0.04. The business had revenue of $3.56 billion during the quarter, compared to analyst estimates of $3.55 billion. IQVIA had a net margin of 8.26% and a return on equity of 31.36%. Sell-side analysts predict that IQVIA Holdings Inc. will post 9.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Morgan Stanley dropped their price target on shares of IQVIA from $260.00 to $240.00 and set an “overweight” rating on the stock in a research note on Thursday, October 27th. Guggenheim increased their target price on shares of IQVIA to $249.00 in a research report on Thursday, October 27th. Citigroup downgraded IQVIA from a “buy” rating to a “neutral” rating and lowered their price target for the company from $275.00 to $245.00 in a research report on Thursday, November 17th. Robert W. Baird lowered their price target on IQVIA from $266.00 to $260.00 and set an “outperform” rating on the stock in a research report on Friday, January 13th. Finally, Barclays raised their price target on IQVIA from $215.00 to $235.00 and gave the company an “overweight” rating in a research report on Thursday, October 27th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $256.73.

About IQVIA

(Get Rating)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.